The 4 biggest pharma market access stories of 2019

What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive into the pharmaphorum archives to find out.

Senate committee backs Hahn as new FDA Commissioner

FDA guidance finally opens door for insulin biosimilars

New draft guidance from the FDA has opened the door for the development of insulin biosimilars, potentially allowing for cheaper near-identical versions of these biologic drugs to be interc

Elsevier gets FDA backing for ‘predictive toxicology’ projec...

FDA approves Alnylam's second RNAi drug - with $442K annual ...

Alnylam has had a second RNA interference (RNAi) drug approved by the FDA, to treat the ultra-rare disease acute hepatic porphyria, with an ultra-high price tag to match.

FDA approves latest Humira near-copy, as dozens of biosimila...

The FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of these cheaper near-copies teed up to compete when the originator’s p